All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

María-Victoria MateosCo-Chair

Professor María-Victoria Mateos is a Consultant Physician in the Hematology Department at the University Hospital of Salamanca, Salamanca, ES, and an Associate Professor of Medicine. She is also the Director of the Myeloma Program and coordinates the Clinical Trials Unit at the University Hospital of Salamanca 

Professor Mateos serves as coordinator of the Spanish Myeloma Group (GEM), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials, especially in the smoldering myeloma setting, which have profoundly influenced current treatment options. 

Professor Mateos is a member of the International Myeloma Working Group, International Myeloma Society (IMS), European School of Haematology (ESH), and American Society of Hematology (ASH). She served on the ASH Scientific Committee on Plasma Cell Diseases between 2015 and 2019 and on the European Hematology Association (EHA) Scientific Program Committee and Advisory Board from 2013 to 2020, acting as chair of the Scientific Program Committee in 2019. In addition, she is a member of the Society of Hematologic Oncology (SOHO) Steering Committee, a member of the IMS board, a member of the ESH Scientific Committee, and was a Councilor on the EHA Board from 2015 for a 4-year mandate. 

Professor Mateos has authored over 400 peer-reviewed publications and frequently presents her work nationally and internationally. She received the Brian Durie Award in 2019 and more recently achieved the Bart Barlogie Clinical Investigator Award, both of which recognize excellence in myeloma research.  

   

|||